16 completed, 3 unknown, 1 withdrawn. 20 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 20 | Completed 16, Unknown 3, Withdrawn 1 |
| Phase 2 | 3 | Completed 1, Unknown 1, Withdrawn 1 |
Follow Dystonia: new trials by email Literature Review of Dystonia trials Research Report on Dystonia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy Placebo, Valbenazine - Dyskinesia, Cerebral Palsy | Phase 3 | Completed | Neurocrine Biosciences | 86 | 2022-04-15 | 2026-04-29 |
| Abobotulinum Toxin and Neubotulinum Toxin Injection in Cerivical Dystonia Neuronox(R), Dysport (R) - Cervical Dystonia | Phase 3 | Completed | Department of Medical Services Ministry of Public Health of Thailand | 52 | 2019-10-25 | 2021-03-09 |
| Neubotulinum Toxin Injection in Cerivical Dystonia Neuronox ® Injection - Cervical Dystonia | Phase 3 | Completed | Department of Medical Services Ministry of Public Health of Thailand | 50 | 2019-01-03 | 2021-09-17 |
| Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS) daxibotulinumtoxinA for injection - Cervical Dystonia | Phase 3 | Completed | Revance Therapeutics, Inc. | 357 | 2018-09-05 | 2022-01-28 |
| Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1) DaxibotulinumtoxinA for injection, Placebo - Cervical Dystonia | Phase 3 | Completed | Revance Therapeutics, Inc. | 301 | 2018-06-20 | 2022-12-05 |
| Meditoxin® Treatment in Patients With Cervical Dystonia Meditoxin, Placebo - Dystonia, Dystonic Disorder | Phase 3 | Completed | Medy-Tox | 66 | 2017-07-06 | 2019-03-27 |
| Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia Botulinum toxin type A - Cervical Dystonia | Phase 3 | Completed | Ipsen | 112 | 2013-03-01 | 2019-08-07 |
| Efficacy and Safety of MEDITOXIN® in Cervical Dystonia Medytoxin, Botox - Cervical Dystonia | Phase 3 | Completed | Medy-Tox | 152 | 2013-01-09 | 2019-04-08 |
| Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia. Botulinum toxin type A, Placebo - Cervical Dystonia | Phase 3 | Completed | Ipsen | 134 | 2013-01-01 | 2019-08-07 |
| Study Comparing Short Term Efficacy of Dysport and Dysport NG to Placebo, and to Assess Efficacy and Safety of Dysport NG of Subjects With Cervical Dystonia Botulinum toxin type A, Placebo - Cervical Dystonia | Phase 3 | Completed | Ipsen | 382 | 2011-04-01 | 2022-09-28 |
| Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles) Botulinum Toxin: Xeomin, Placebo - Parkinson's Disease, Foot Dystonia | Phase 3 | Unknown | University Hospital, Clermont-Ferrand | 45 | 2009-09-01 | 2011-03-25 |
| Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation Dexmedetomidine Hydrochloride Infusion, Normal Saline - Parkinson's Disease, Essential Tremor | Phase 2 / Phase 3 | Withdrawn | Vanderbilt University | 2008-01-01 | 2014-07-01 | |
| IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia incobotulinumtoxinA (Xeomin) (240 Units), incobotulinumtoxinA (Xeomin) (120 Units), Placebo - Cervical Dystonia | Phase 3 | Completed | Merz Pharmaceuticals GmbH | 233 | 2006-07-01 | 2013-07-19 |
| Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia Botulinum toxin type A - Cervical Dystonia | Phase 3 | Completed | Ipsen | 108 | 2006-02-01 | 2022-09-28 |
| Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia Botulinum toxin type A, Placebo - Cervical Dystonia | Phase 3 | Completed | Ipsen | 116 | 2005-10-10 | 2022-09-28 |
| Double-blind, Multicenter Study to Assess the Efficacy of Bilateral Pallidal Stimulation in Patients With Medically Refractory Primary Cervical Dystonia Deep brain stimulation (DBS) - Cervical Dystonia | Phase 3 | Completed | German Parkinson Study Group (GPS) | 63 | 2005-07-01 | 2018-02-19 |
| Bilateral Internal Pallidum Stimulation in Primary Generalized Dystonia deep brain stimulation of the internal globus pallidus - Dystonia, Primary Generalized Dystonia | Phase 2 / Phase 3 | Unknown | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 24 | 2005-02-01 | 2006-01-05 |
| Study to Assess the Efficacy and Safety of Dysport® in Cervical Dystonia Botulinum toxin type A - Cervical Dystonia | Phase 3 | Completed | Ipsen | 516 | 2004-10-01 | 2023-03-30 |
| Deep Brain Stimulation in Treating Patients With Dystonia implanted pulse generator - Dystonia | Phase 2 / Phase 3 | Completed | Icahn School of Medicine at Mount Sinai | 15 | 1997-09-01 | 2015-03-25 |
| Pallidal Stimulation in Patients With Idiopathic Generalised Dystonia Deep brain stimulation - Dystonia | Phase 3 | Unknown | Groupe Hospitalier Pitie-Salpetriere | 2007-08-29 |
Torticollis (13) · Parkinson Disease (2) · Athetosis (1) · Cerebral Palsy (1) · Chorea (1) · Dyskinesias (1) · Dystonic Disorders (1) · Essential Tremor (1) · Mental Disorders (1) · Neurologic Manifestations (1) · Rare Diseases (1)
Pathological Conditions, Signs and Symptoms (20) · Signs and Symptoms (20) · Dyskinesias (19) · Neurologic Manifestations (19) · Nervous System Diseases (7) · Central Nervous System Diseases (4) · Movement Disorders (4) · Brain Diseases (3) · Basal Ganglia Diseases (2) · Neurodegenerative Diseases (2) · Parkinsonian Disorders (2) · Synucleinopathies (2) · Brain Damage, Chronic (1) · Disease Attributes (1)
Botulinum Toxins, Type A (11) · abobotulinumtoxinA (7) · Deep Brain Stimulation (2) · Injections (2) · Dexmedetomidine (1) · Injections, Intramuscular (1) · Saline Solution (1) · incobotulinumtoxinA (1) · valbenazine (1)
Ipsen (6) · Department of Medical Services Ministry of Public Health of Thailand (2) · Medy-Tox (2) · Revance Therapeutics, Inc. (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · German Parkinson Study Group (GPS) (1) · Groupe Hospitalier Pitie-Salpetriere (1) · Icahn School of Medicine at Mount Sinai (1) · Merz Pharmaceuticals GmbH (1) · Neurocrine Biosciences (1) · University Hospital, Clermont-Ferrand (1) · Vanderbilt University (1)
United States (10) · Austria (5) · France (5) · Germany (5) · Poland (4) · Czechia (3) · Russia (3) · Spain (3) · Belgium (2) · Canada (2) · Portugal (2) · Thailand (2) · United Kingdom (2) · Argentina (1) · Australia (1)
Cynthia Comella, M.D. (1) · Franck Durif (1) · Hans Speelman, PhD (1) · Joerg Mueller, MD (1) · Joseph Neimat, M.D. (1) · Marie Vidailhet, MD, PhD (1) · Mitchell Francis Brin (1) · Subsai Kongsaengdao (1)
PMID 20359934, PMID 25324317, PMID 15689584, PMID 21764407, PMID 22021883, PMID 23604344, PMID 23779062, PMID 25127231, PMID 26074391, PMID 27653448, PMID 28138245, PMID 29731634, PMID 32884828, PMID 33524060, PMID 38295339, PMID 40439027
2005 (2), 2004 (1)